So far, MRD assessment by liquid biopsy (ctDNA) has not been used to predict postoperative treatment efficacy and recurrence risk of GIST patients because of special disease characteristics and technological limitations. Therefore, we conducted this prospective multi-center, single-arm observational study to collect 45 operable patients with locally advanced, suspected high-risk GIST. NGS genetic testing platform is used to detect tumour tissues and peripheral ctDNA will also be dectected. we try to explore the correlation between PFS/OS and MRD in high-risk GIST patients by analyzing the relationship between dynamic changes in ctDNA mutation spectrum and postoperative adjuvant therapy efficacy, and to evaluate MRD-based genomic characteristics to guide further treatment.
Patients aged between 18 and 80
Patients suspected for high-risk GIST by preoperative imaging examinations or diagnosed with high-risk GIST by pathological biopsy, who have not received preoperative neoadjuvant treatment
Patients must have not received any treatment including radiotherapy, chemotherapy or surgery
The function of other organs including liver and kidneys is good enough so that the patients could tolerate targeted therapy and surgery
Previous medical history of malignant tumors or synchronous other malignancies
Emergent surgery because of bowel obstruction, perforation or bleeding
Pregnant or lactant women
Medical history of severe mental illness